Screener
BioCryst Pharmaceuticals BCRX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
FAQ
- What is BioCryst Pharmaceuticals's accounts payable?
- BioCryst Pharmaceuticals (BCRX) reported accounts payable of $11.46M in Q2 2026.
- How has BioCryst Pharmaceuticals's accounts payable changed year-over-year?
- BioCryst Pharmaceuticals's accounts payable increased by 33.4% year-over-year, from $8.59M to $11.46M.
- What is the long-term trend for BioCryst Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's accounts payable has grown at a -3.3% compound annual growth rate (CAGR), from $18.71M to $15.83M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about BioCryst Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude